Varun Grover Regeneron
How would you describe PCMG to someone in no more than 20 words?
“A great platform for professional development… [with] access to valuable, actionable insights from industry experts… very inclusive, a unique format.”
What attracted you to join PCMG as a member and what do you do for PCMG?
“PCMG is a great platform for professional development…My involvement in PCMG spans about nine years. The last three to six years, I’ve been helping support the PCMG annual assembly as one of the sub team leads., and recently I’ve elected to help support in the capacity of a treasurer.”
What benefit did you gain from joining the committee?
“Access to tools and templates, access to valuable, actionable insights from industry experts who have really helped me drive proven clinical outsourcing strategies in my day role.”
What experiences weren’t you expecting before you joined the Committee which proved useful in the workplace?
“Access to industry experts who are not only helping stay ahead of the curve… but they also allow for a lot of knowledge sharing, cross-pollination between large pharma, small biotech, CROs, ancillary vendors.”
“There is a lot of areas for professional development… [allowing me to] learn and adapt to the ever changing market conditions.”
How has membership of the Committee changed your working perspectives?
“I’ve personally had… access to valuable, actionable insights from industry experts who have really helped me drive proven clinical outsourcing strategies in my day role.”
“Being able to learn from industry experts at PCMG… is a great learning curve for me and for the community as a whole.”
What are the major changes in the outsourcing landscape that are affecting members of PCMG?
“The biggest change I’ve seen is the shift in the pendulum once again from an FSO to an FSP model.
“Many of the pharma biotech players are moving towards an FSP type approach… to reduce the complexity, to increase productivity and efficiency… to reduce costs.
The introduction of AI, how will that impact the way in which we conduct clinical trials?
Uncertainty around tariffs, the post-COVID implications to clinical trials, financial pressures with rising inflation…”
What piece of advice would you give someone considering putting themselves forward for a place on the PCMG Committee?
“If you want to be an enabler to move ahead with the changing dynamic market conditions… then PCMG is definitely at the forefront of change and the future of outsourcing.”